98 related articles for article (PubMed ID: 37489008)
1. Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling.
He H; Guo J; Hu Y; Zhang H; Li X; Zhang J; Jin S
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1404-1414. PubMed ID: 37489008
[TBL] [Abstract][Full Text] [Related]
2. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
3. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.
Sang C; Yan L; Lin J; Lin Y; Gao Q; Shen X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):199. PubMed ID: 38627278
[TBL] [Abstract][Full Text] [Related]
5. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K
J Hepatol; 2024 Apr; ():. PubMed ID: 38679071
[TBL] [Abstract][Full Text] [Related]
6. Fasting-induced RNF152 resensitizes gallbladder cancer cells to gemcitabine by inhibiting mTORC1-mediated glycolysis.
Tao Y; Gong Z; Shen S; Ding Y; Zan R; Zheng B; Sun W; Ma C; Shu M; Lu X; Liu H; Ni X; Liu H; Suo T
iScience; 2024 May; 27(5):109659. PubMed ID: 38706841
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
Edeline J; Bridgewater J; Campillo-Gimenez B; Neveu E; Phelip JM; Neuzillet C; Boudjema K; Rolland Y; Valle JW; Garin E; Malka D; Lamarca A
Hepatology; 2024 Jan; 79(1):96-106. PubMed ID: 37505216
[TBL] [Abstract][Full Text] [Related]
8. Discordant microsatellite instability findings in two samples from a patient with biliary cancer that responded to pembrolizumab.
Matsubayashi H; Todaka A; Ishiwatari H; Sato J; Niiya F; Kondo T; Ono H; Yamazaki K; Sasaki K; Kiyozumi Y
Clin J Gastroenterol; 2023 Oct; 16(5):748-754. PubMed ID: 37490248
[TBL] [Abstract][Full Text] [Related]
9. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract][Full Text] [Related]
10. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma.
Li Z; Qin C; Zhao B; Wang Y; Li T; Zhao Y; Wang W
PLoS Genet; 2023 Jul; 19(7):e1010847. PubMed ID: 37506056
[TBL] [Abstract][Full Text] [Related]
11. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.
Liu LN; Cui YS; Fang BJ
Asian J Surg; 2023 Dec; 46(12):5482-5483. PubMed ID: 37541902
[No Abstract] [Full Text] [Related]
13. Glycolytic enzyme PKM2 regulates cell senescence but not inflammation in the process of osteoarthritis.
Liu B; Wang C; Weng Z; Yang Y; Zhao H; Zhang Y; Fei Q; Shi Y; Zhang C
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1425-1433. PubMed ID: 37525533
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting pH responsive chitosan nanoparticles for enhanced active cellular internalization of gemcitabine in non-small cell lung cancer.
Kumar K; Rawat SG; Manjit ; Mishra M; Priya ; Kumar A; Chawla R
Int J Biol Macromol; 2023 Sep; 249():126057. PubMed ID: 37524283
[TBL] [Abstract][Full Text] [Related]
15.
Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
[No Abstract] [Full Text] [Related]
16. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma.
Testoni SGG; Minici C; Benetti E; Clemente F; Boselli D; Sciorati C; De Monte L; Petrone MC; Enderle M; Linzenbold W; Protti MP; Manfredi A; De Cobelli F; Reni M; Falconi M; Capurso G; Arcidiacono PG; Della-Torre E
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509365
[TBL] [Abstract][Full Text] [Related]
17. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1a receptor knockout ameliorates high-fat diet-induced cardiac dysfunction by regulating glucose and lipid metabolism.
Wang J; Li D; Zhang Y; Xing D; Lei Z; Jiao X
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1380-1392. PubMed ID: 37501512
[TBL] [Abstract][Full Text] [Related]
19. miR-205-5p inhibits homocysteine-induced pulmonary microvascular endothelium dysfunction by targeting FOXO1.
Huang X; Li Z; Zhang L; Yang Y; Wang Y; Li S; Li G; Feng H; Yang X
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1456-1466. PubMed ID: 37491880
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Nishi H; Gotoh K; Tomimaru Y; Kobayashi S; Sasaki K; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Takahashi H; Tanemura M; Doki Y; Eguchi H
Cancer Chemother Pharmacol; 2023 Oct; 92(4):303-314. PubMed ID: 37491611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
